AstraZeneca and Merck’s ovarian cancer drug, Lynparza, has received U.S. FDA approval for the treatment of advanced pancreatic cancer.
The PARP inhibitor is now the only approved drug in biomarker-selected patients with advanced pancreatic cancer.
In a pivotal Phase III trial, Lynparza reduced the risk of disease progression or death by 47% in patients whose disease had not progressed on at least 16 weeks of a 1st-line platinum-based chemotherapy regimen.
Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, regardless of BRCA status. It is approved in the U.S., the EU, Japan, China and several other countries as 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer following response to platinum-based chemotherapy. It is also approved in 44 countries, including the US and Japan, for BRCA-mutated, HER2-negative, metastatic breast cancer.
Read the press release
